<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40949672</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2055-2076</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Digital health</Title><ISOAbbreviation>Digit Health</ISOAbbreviation></Journal><ArticleTitle>A randomised clinical trial to evaluate a digital therapeutic (TH-001) for improving glycaemic control in adults with prediabetes.</ArticleTitle><Pagination><StartPage>20552076251376260</StartPage><MedlinePgn>20552076251376260</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20552076251376260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/20552076251376260</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="UNASSIGNED">Prediabetes, characterized by elevated blood glucose levels below diabetes diagnostic thresholds, presents a significant global health challenge due to high prevalence and associated risks for developing type 2 diabetes. Traditional diabetes prevention programs (DPPs) often face challenges in scalability and accessibility, particularly in underserved communities. Digital therapeutics (DTx), like TH-001, offer potential scalable solutions requiring clinical validation. This randomized, open-label, controlled, parallel-group clinical trial aimed to evaluate the efficacy and safety of TH-001, a digital therapeutic application, reducing hemoglobin A1c (HbA1c) among adults with prediabetes over a 90-day intervention period.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">68 eligible adults were randomly assigned to either standard care alone or standard care plus the TH-001 intervention. Primary outcomes measured were glycaemic parameters including HbA1c, fasting glucose, 2-h post-load glucose from an oral glucose tolerance test, and insulin levels, while secondary outcomes included anthropometric measures. User engagement metrics were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The intervention significantly reduced HbA1c levels (mean difference -0.22%, <i>p&#x2009;=&#x2009;</i>.023) and body weight (-2.53&#x2005;kg, <i>p&#x2009;&lt;&#x2009;</i>.001) compared to the control group. Although fasting glucose and insulin levels showed positive trends, differences were not statistically significant. User engagement was high, correlating strongly with HbA1c reduction (<i>r&#x2009;=&#x2009;</i>.95, <i>p&#x2009;&lt;&#x2009;</i>.001), demonstrating the critical role of sustained interaction with TH-001.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">TH-001 demonstrates significant effectiveness in HbA1c reduction and body weight, with strong user engagement suggesting it may effectively overcome traditional barriers of DPPs. Long-term studies are needed to confirm sustained benefits.Efficacy and Safety of Digital Therapeutic in Adults with Prediabetes; https://clinicaltrials.gov/study/NCT05668819; ClinicalTrials.gov ID: NCT05668819.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cakmak</LastName><ForeName>Ramazan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3815-7444</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Istinye University, &#x130;stanbul, Turkey.</Affiliation><Identifier Source="RINGGOLD">469683</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>&#x130;lker</ForeName><Initials>&#x130;</Initials><Identifier Source="ORCID">0000-0002-3710-4706</Identifier><AffiliationInfo><Affiliation>Tesu Health, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avcu</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0003-0597-5173</Identifier><AffiliationInfo><Affiliation>Tesu Health, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birer</LastName><ForeName>G&#xfc;rkan Caner</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0001-7236-5613</Identifier><AffiliationInfo><Affiliation>Tesu Health, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akgul</LastName><ForeName>Ozer</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-3802-3270</Identifier><AffiliationInfo><Affiliation>Istanbul Health and Technology University, Istanbul, Turkey.</Affiliation><Identifier Source="RINGGOLD">578738</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saini</LastName><ForeName>Kamal S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0001-6301-3309</Identifier><AffiliationInfo><Affiliation>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">89744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carnell</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0000-4856-1999</Identifier><AffiliationInfo><Affiliation>Brynderwen Surgery, Cardiff, UK.</Affiliation><Identifier Source="RINGGOLD">433629</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutlu</LastName><ForeName>Orkide</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-4402-2231</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Prof Dr Cemil Tascioglu City Hospital, Istanbul, Turkey.</Affiliation><Identifier Source="RINGGOLD">64157</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05668819</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Digit Health</MedlineTA><NlmUniqueID>101690863</NlmUniqueID><ISSNLinking>2055-2076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pre-diabetic state</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">digital health</Keyword><Keyword MajorTopicYN="N">glycemic control</Keyword><Keyword MajorTopicYN="N">healthy lifestyle</Keyword><Keyword MajorTopicYN="N">type 2/prevention and control</Keyword></KeywordList><CoiStatement>&#x130;.T., H.A. and G.C.B. are employees and shareholders of the study sponsor. K.S.S. reports consulting fees from the European Commission, and stock and/or other ownership interests in Labcorp Inc., Fortrea Inc., and Quantum Health Analytics (UK) Ltd., outside the submitted work. The other authors do not report any conflicts of interest. To manage potential conflicts of interest, data analysis was conducted by independent co-authors (O.A. and O.K.) not affiliated with the study sponsor, and the study was overseen by the Istinye University Clinical Research Ethics Committee, which had no financial ties to Tesu Health. The sponsor, Tesu Health, had no role in data collection, data analysis, data interpretation beyond providing the digital therapeutic software and funding. All authors, including those with financial interests, reviewed and approved the final manuscript, ensuring compliance with the Digital Health Journal's policy on authorship and transparency.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>7</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40949672</ArticleId><ArticleId IdType="pmc">PMC12432327</ArticleId><ArticleId IdType="doi">10.1177/20552076251376260</ArticleId><ArticleId IdType="pii">10.1177_20552076251376260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tab&#xe1;k &#xc1;G, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279&#x2013;2290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891203</ArticleId><ArticleId IdType="pubmed">22683128</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmaki P, Damaskos C, Garmpis N, et al. Complications of the type 2 diabetes mellitus. Curr Cardiol Rev 2021; 16: 249&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903505</ArticleId><ArticleId IdType="pubmed">33407062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W, Hsieh T, Hsu W-L, et al. Diabetes and further risk of cancer: a nationwide population-based study. BMC Med 2024; 22: 214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11134680</ArticleId><ArticleId IdType="pubmed">38807177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 2017; 60: 1022&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5632944</ArticleId><ArticleId IdType="pubmed">28265721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosenzon O, Cheng A, Rabinstein AA, et al. Diabetes and stroke: what are the connections? J Stroke 2023; 25: 26&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9911852</ArticleId><ArticleId IdType="pubmed">36592968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao F, Yang F, Li J, et al. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetol Metab Syndr 2024; 16: 101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11092065</ArticleId><ArticleId IdType="pubmed">38745237</ArticleId></ArticleIdList></Reference><Reference><Citation>Punthakee Z, Goldenberg R, Katz P. 2018 Clinical practice guidelines definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2018; 42: S10&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuomilehto J, Lindstr&#xf6;m J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333990</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowler WC, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370926</ArticleId><ArticleId IdType="pubmed">11832527</ArticleId></ArticleIdList></Reference><Reference><Citation>Saaristo T, Peltonen M, Kein&#xe4;nen-Kiukaanniemi S, et al. National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health 2007; 66: 101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515250</ArticleId></ArticleIdList></Reference><Reference><Citation>10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009; 374: 1677&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135022</ArticleId><ArticleId IdType="pubmed">19878986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes RE, Cameron E, Cotterill S, et al. The NHS Diabetes Prevention Programme: an observational study of service delivery and patient experience. BMC Health Serv Res 2020; 20: 1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694420</ArticleId><ArticleId IdType="pubmed">33246460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SE, Castro CM, Cho EH, et al. Evaluation of a digital diabetes prevention program adapted for low-income patients, 2016&#x2013;2018. Prev Chronic Dis 2019; 16: E155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6896833</ArticleId><ArticleId IdType="pubmed">31775010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender A, Donde S, Silva M, et al. Adoption of digital therapeutics in Europe. Ther Clin Risk Manag 2024; 20: 939&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11687304</ArticleId><ArticleId IdType="pubmed">39741688</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman MA, Guthrie NL, Edwards KL, et al. Change in glycemic control with use of a digital therapeutic in adults with type 2 diabetes: cohort study. JMIR Diabetes 2018; 3: e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238888</ArticleId><ArticleId IdType="pubmed">30291074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia J, Guthrie NL, Lupinacci P, et al. Randomized, controlled trial of a digital behavioral therapeutic application to improve glycemic control in adults with type 2 diabetes. Diabetes Care 2022; 45: 2976&#x2013;2981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9862458</ArticleId><ArticleId IdType="pubmed">36181554</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xde;orgeirsson T, Torfad&#xf3;ttir JE, Egilsson E, et al. Randomized trial for weight loss using a digital therapeutic application. J Diabetes Sci Technol 2022; 16: 1150&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9445341</ArticleId><ArticleId IdType="pubmed">33736484</ArticleId></ArticleIdList></Reference><Reference><Citation>Block G, Azar KM, Romanelli RJ, et al. Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: a randomized controlled trial among persons with prediabetes. J Med Internet Res 2015; 17: e240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642405</ArticleId><ArticleId IdType="pubmed">26499966</ArticleId></ArticleIdList></Reference><Reference><Citation>Katula JA, Dressler EV, Kittel C, et al. Effects of a digital diabetes prevention program: an RCT. Am J Prev Med 2022; 62: 567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">35151522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebede M, Zeeb H, Peters M, et al. Effectiveness of digital interventions for improving glycemic control in persons with poorly controlled type 2 diabetes: a systematic review, meta-analysis, and meta-regression analysis. Diabetes Technol Ther 2018; 20: 767&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">30257102</ArticleId></ArticleIdList></Reference><Reference><Citation>Howarth E, Bower PJ, Kontopantelis E, et al. &#x2018;Going the distance&#x2019;: an independent cohort study of engagement and dropout among the first 100 000 referrals into a large-scale diabetes prevention program. BMJ Open Diabetes Res Care 2020; 8: e001835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733095</ArticleId><ArticleId IdType="pubmed">33303493</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob R, Harperink S, Rudolf AM, et al. Factors influencing adherence to mHealth apps for prevention or management of noncommunicable diseases: systematic review. J Med Internet Res 2022; 24: e35371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178451</ArticleId><ArticleId IdType="pubmed">35612886</ArticleId></ArticleIdList></Reference><Reference><Citation>Everett E, Kane B, Yoo A, et al. A novel approach for fully automated, personalized health coaching for adults with prediabetes: pilot clinical trial. J Med Internet Res 2018; 20: e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849796</ArticleId><ArticleId IdType="pubmed">29487046</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm TF, Udsen FW, Giese IE, et al. The effectiveness of digital health lifestyle interventions on weight loss in people with prediabetes: a systematic review, meta-analysis, and meta-regression. J Diabetes Sci Technol 2024: 19322968241292646. DOI: 10.1177/19322968241292646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19322968241292646</ArticleId><ArticleId IdType="pmc">PMC11571619</ArticleId><ArticleId IdType="pubmed">39508277</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwashmi MF, Mugford G, Abu-Ashour W, et al. A digital diabetes prevention program (transform) for adults with prediabetes: secondary analysis. JMIR Diabetes 2019; 4: e13904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688434</ArticleId><ArticleId IdType="pubmed">31350833</ArticleId></ArticleIdList></Reference><Reference><Citation>Batten R, Alwashmi MF, Mugford G, et al. A 12-month follow-up of the effects of a digital diabetes prevention program (VP transform for prediabetes) on weight and physical activity among adults with prediabetes: secondary analysis. JMIR Diabetes 2022; 7: e23243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8800085</ArticleId><ArticleId IdType="pubmed">35029532</ArticleId></ArticleIdList></Reference><Reference><Citation>Valabhji J, Barron E, Bradley D, et al. Early outcomes from the English National Health Service diabetes prevention programme. Diabetes Care 2020; 43: 152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115827</ArticleId><ArticleId IdType="pubmed">31719054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross J, Barron E, McGough B, et al. Uptake and impact of the English National Health Service digital diabetes prevention programme: observational study. BMJ Open Diabetes Res Care 2022; 10: e002736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066480</ArticleId><ArticleId IdType="pubmed">35504697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely E, Gruss SM, Luman ET, et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC&#x2019;s National Diabetes Prevention Program. Diabetes Care 2017; 40: 1331&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606310</ArticleId><ArticleId IdType="pubmed">28500215</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz Z, Absetz P, Oldroyd J, et al. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci 2015; 10: 172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681022</ArticleId><ArticleId IdType="pubmed">26670418</ArticleId></ArticleIdList></Reference><Reference><Citation>Baucom KJW, Bauman T, Chavez MG, et al. Barriers to participation and lifestyle change among lower versus higher income participants in the National Diabetes Prevention Program: lifestyle coach perspectives. Transl Behav Med 2022; 12: 860&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385121</ArticleId><ArticleId IdType="pubmed">35554612</ArticleId></ArticleIdList></Reference><Reference><Citation>McMullen B, Duncanson K, Collins CE, et al. A systematic review of the mechanisms influencing engagement in diabetes prevention programmes for people with pre-diabetes. Diabetic Med 2024; 41: e15323.</Citation><ArticleIdList><ArticleId IdType="pubmed">38829966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Guo Y, Hong Y, et al. Dose&#x2013;response effects of patient engagement on health outcomes in an mHealth intervention: secondary analysis of a randomized controlled trial. JMIR mHealth uHealth 2022; 10: e25586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767469</ArticleId><ArticleId IdType="pubmed">34982724</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss G, Flannery J, Vierra E, et al. Meaningful engagement: a cross functional framework for digital therapeutics. Front Digit Health 2022; 4: 890081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426459</ArticleId><ArticleId IdType="pubmed">36052316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Ma X, Guan C, et al. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol 2022; 21: 74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107726</ArticleId><ArticleId IdType="pubmed">35568946</ArticleId></ArticleIdList></Reference><Reference><Citation>Shubrook JH, Neumiller JJ, Wright E. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Postgrad Med 2022; 134: 376&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">34817311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioana M, Deng J, Nadarajah A, et al. Global prevalence of diabetic retinopathy in pediatric type 2 diabetes a systematic review and meta-analysis. JAMA Netw Open 2023; 6: e231887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10024209</ArticleId><ArticleId IdType="pubmed">36930156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Wang J, Yang S, et al. Effect of intermittent fasting diet on glucose and lipid metabolism and insulin resistance in patients with impaired glucose and lipid metabolism: a systematic review and meta-analysis. Int J Endocrinol 2022; 2022: 6999907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970877</ArticleId><ArticleId IdType="pubmed">35371260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M, Dai S, Skeete RA, et al. An examination of gender differences in the national diabetes prevention program&#x2019;s lifestyle change program. Diabetes Educ 2020; 46: 580&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802597</ArticleId><ArticleId IdType="pubmed">33063641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>